SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 79 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $867,000 | +182.4% | 79,000 | +125.7% | 0.02% | +400.0% |
| Q4 2019 | $307,000 | +17.6% | 35,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $261,000 | -19.9% | 35,000 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $326,000 | -60.4% | 35,000 | -65.6% | 0.00% | -50.0% |
| Q3 2018 | $823,000 | +131.8% | 101,800 | +101.6% | 0.01% | +100.0% |
| Q2 2018 | $355,000 | -50.6% | 50,500 | 0.0% | 0.00% | -50.0% |
| Q1 2018 | $719,000 | +62.7% | 50,500 | 0.0% | 0.01% | +60.0% |
| Q4 2017 | $442,000 | -25.2% | 50,500 | 0.0% | 0.01% | -28.6% |
| Q3 2017 | $591,000 | -16.2% | 50,500 | 0.0% | 0.01% | -12.5% |
| Q2 2017 | $705,000 | +1.7% | 50,500 | 0.0% | 0.01% | 0.0% |
| Q1 2017 | $693,000 | – | 50,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |